Innovative AAV Manufacturing Platform
FUEL™
As gene therapy developers push the boundaries of innovation, manufacturing must keep pace. Forge’s FUEL™ platform delivers a more efficient manufacturing foundation — with advanced technologies, proven processes, and product-specific optimizations to propel your program forward.

advanced technology
pEMBR™ 2.0 Ad Helper
As one of the smallest Ad helpers commercially available at 8.9 kb, pEMBR™ 2.0 increases manufacturing efficiency, offers an improved safety profile by reducing unnecessary adenoviral components for AAV production, and is Forge-specific intellectual property.

advanced technology
Modified Rep/Caps
Designed for safety and higher AAV yields, Forge’s patent pending modified rep/cap incorporates the client-specific capsid sequence into its proprietary backbone plasmid.

advanced technology
Ignition Cells™
Our suspension HEK293 Ignition Cells™ are optimized for robust transient transfection and can achieve over 90% full capsids post-enrichment, often with undetectable particles. Ignition Cells™ are supported by fully qualified Master Cell Bank and Working Cell Bank.
Novel Capsid? Yeah, Our Platform Can Work With That.
The FUEL™ platform is designed to support all serotypes, including novel capsids.
Higher Yield, Better Recovery, Same Unmatched Quality
Explore how FUEL™ boosts productivity, scales seamlessly, improves recovery, and maintains consistent quality.
Product-Specific Optimizations
FUEL™ offers a strong foundation for further enhancements, combining platform technologies with product-specific optimizations to help you achieve high yield, consistent quality, and reliable performance. Here are some of the optimizations we’ve used to help developers achieve their goals.
Yield Optimization
Downstream Scalability
Downstream Recovery

Ready to Fuel Your Program?
Let’s talk about how we can help accelerate your therapy to patients.
Frequently Asked Questions
Does Forge Biologics provide AAV CRO services?
Forge Biologics is a CDMO (Contract Development and Manufacturing Organization) and does not provide CRO services. We specialize in AAV manufacturing, offering research-grade production, process development, GMP manufacturing, and integrated support services such as molecular development, analytics, and regulatory consultation. While we don’t provide traditional CRO services—like preclinical or clinical trial management—we work closely with clients to support their manufacturing strategy throughout the development lifecycle and maintain preferred partnerships with CROs that we can connect our clients to as needed.
How quickly can Forge deliver a GMP batch?
Timelines for GMP batch delivery are highly dependent on the specifics of your program, including vector design, process readiness, and scope of work. By partnering with Forge and leveraging our proprietary platform and integrated services—such as in-house analytics and plasmid production—developers may accelerate timelines to GMP manufacturing by up to 30% compared to full process development. Connect with our Client Development team to discuss your program and receive a more detailed scope of work based on your program needs.
What additional services does Forge provide?
Watch a member of our Technical Sales team tell you more about Forge’s innovative FUEL™ platform.
Hot off the Forge
-
Forge Biologics Announces AAV Development and cGMP Manufacturing Relationship with Fractyl Health to Advance Their Gene Therapy Platform for Patients with Metabolic Diseases
Fractyl Health will leverage Forge’s FUEL™ platform to manufacture AAV for Rejuva, Fractyl’s pancreatic gene therapy platform for patients with obesity and type 2 diabetes.
-
Forge Biologics Announces Eight Presentations at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting
Oral and poster presentations will highlight data demonstrating the enhanced productivity, recovery, and consistent quality of Forge’s FUEL™ AAV manufacturing platform
-
Forge Biologics Announces the FUEL™ AAV Manufacturing Platform
FUEL™ platform can achieve a 2-6x increase in productivity compared to industry standard, and includes pEMBR 2.0™ Ad helper and modified rep/cap plasmids.
-
Ray Therapeutics and Forge Biologics Expand Their Viral Vector cGMP Partnership to Encompass Plasmid DNA Manufacturing
Building on an AAV manufacturing partnership with new plasmid production, Forge’s end-to-end manufacturing services will help to advance Ray’ gene therapy for patients living with retinitis pigmentosa and other blinding…